ClinicalTrials.gg
Not yet recruitingNCT05864508OT-DEFIUpdated May 18, 2023

Interest of Oxytocin as an Adjuvant Treatment of Psycho-educational Measures in Challenging Behaviors in Children With Autism Spectrum Disorders and Moderate to Severe Intellectual Disability: Feasibility and Safety Study.

A Phase 2 interventional study of Oxytocin nasal spray in Autism Spectrum Disorder, sponsored by University Hospital, Toulouse. Not yet recruiting at 1 site in France. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2023-05-18.

Sponsored by University Hospital, Toulouse · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
6 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies testing oxytocin in Autism Spectrum Disorder — 2 open to participants now, 2 under way, none of them phase 3. Oxytocin · Autism Spectrum Disorder.

Planned enrollment
12th of 23
30 · median 30
Started
2023
the only one that year
Phase 2
13 of 23
2 open now
Registered
22nd of 23
by date

Among the 23 studies testing oxytocin in Autism Spectrum Disorder, this one is the 12th largest by planned enrollment, is the only one that started in 2023, is one of 13 in phase 2, and was the 22nd registered.

Autism Spectrum Disorder

1,733 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.

Browse Autism Spectrum Disorder studies →

Open to participants now

2 of the 23 studies testing oxytocin in Autism Spectrum Disorder are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About oxytocin

Oxytocin: first FDA approval 1980 (SYNTOCINON). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 351 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 296 (84%) stop at 75 or younger; 301 take children under 18; 92 take healthy volunteers.

This study: 6 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing oxytocin in Autism Spectrum Disorder, or all of them as a file.
02

Study summary

The investigation team propose in this study to specifically evaluate the feasibility of using oxytocin in the form of an intranasal spray in a specific population of children with autism spectrum disorder and intellectual disability. The lack of studies centered on this population on the one hand, and on the other hand the severity of challenging behaviors presented by these children, make questionable the direct transfer of methods of care used in patients who do not present these challenging behavior. In this sense, the establishment of oxytocin treatment in these children requires a preliminary phase of feasibility assessment before being able to consider a comparative trial of the randomized clinical trial type.

Read the detailed description

Taking into account:

  • Intellectual disability comorbidity as a risk factor for challenging behaviors in the population with autism spectrum disorder;
  • behavioral difficulties inherent in the presence of these behaviors, which are all potential obstacles to the administration of a treatment and therefore above all raise the question of the feasibility of administering such a treatment;
  • the difficulty for children associating autism spectrum disorder of severe intensity and intellectual disability to benefit from clinical and paraclinical examinations given the concern generated by such examinations and challenging behaviors which can then occur in them, raising the question of feasibility monitoring protocol
  • results of Oxytocin administration obtained in patients with autism spectrum disorder without associated intellectual disability;
  • the favorable drug safety profile of oxytocin in children with autism spectrum disorder of the same age but without challenging behaviors;
  • the extreme need for an effective treatment to control challenging behaviors in children with autism spectrum disorder with associated intellectual disability,

the investigation team propose in this study to specifically evaluate the feasibility of using oxytocin in the form of an intranasal spray in a specific population of children with autism spectrum disorder and intellectual disability. The lack of studies centered on this population on the one hand, and on the other hand the severity of challenging behaviors presented by these children, make questionable the direct transfer of methods of care used in patients who do not present these challenging behavior. In this sense, the establishment of oxytocin treatment in these children requires a preliminary phase of feasibility assessment before being able to consider a comparative trial of the randomized clinical trial type.

03

Conditions studied

  • Autism Spectrum Disorder

Keywords

  • Autism Spectrum disorder
  • Oxytocin
  • Intellectual disability
  • Challenging behavior
04

Who can participate

Ages eligible
6 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Minor benefiting from a social security scheme.
  • Diagnosis:autism spectrum disorder according to the Diagnostic and Statistical Manual DSM -5 of severe intensity;
  • Comorbidities:
  • Moderate to severe intellectual disability
  • Presence of challenging behavior objectified by means of clinical examination and the ABC and ABC-I scales
  • Multi-professional psycho-educational and re-educational care : global and coordinated interventions associating, according to the needs, educational interventions by targeted objectives, therapeutic interventions involving functions that do not develop spontaneously, adaptation of the environment by structuring time and space, in close collaboration with the families.
  • If prescribed psychotropic treatments (antipsychotics, anxiolytics, hypnotics/sedatives, antidepressants, psychostimulants and antiepileptics), the dosages must be stable for 3 months*
  • Understanding of French by both parents (if applicable) and ability for both parents to understand, in particular, the instructions for administering the product and to answer questionnaires.
  • signed by the holders of parental authority

Exclusion criteria

Exclusion Criteria:

  • The refusal of the holders of parental authority
  • Pregnant girls, determined by a positive baseline blood pregnancy test
  • Criteria respecting the Syntocinon SPC:

    • to Syntocinon
    • Hyponatremia \< 135 mmol/L
    • Hypokalaemia \< 3.5 mmol/L
    • Hypertension or hypotension
  • Behavioral intolerance to the intranasal route
  • Hepatic impairment ( and/or AST > 3N)
  • Kidney failure (creatinine > 3 N)
  • History of an considered to be abnormal (validated by a cardiologist)
  • Type 1 or 2 diabetes
  • Prolongation of the and/or family history of QT prolongation linked to an identified genetic etiology (QTc prolongation threshold > 460 ms). **
  • History of epilepsy or seizures
  • Sexually active women of childbearing age without effective *
  • Breastfeeding women
  • Severe cardiovascular disease (tachycardia, bradycardia, arrhythmias, hypertension, hypotension, myocardial ischemia)
  • Latex allergy
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    intranasal oxytocin

    intranasal oxytocin treatment once a day during 6 weeks

    Drug: Oxytocin nasal spray

Interventions

06

What researchers measure

Primary outcomes

  1. percentage of children with complete OT administration protocol

    percentage of children who will complete the OT administration protocol

    Time frame: Week 14

  2. percentage of children with complete monitoring protocol

    percentage of children who will complete the monitoring protocol

    Time frame: week 14

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2023; primary completion for Dec 2026, 41 months later.

Of 68 non-industry phase 2 interventional studies under Autism Spectrum Disorder, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 63. This study's planned 41 months is close to that.

Counting every sponsor, half of 83 studies reached it within 36 months; a quarter within 23 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2023
First posted
May 18, 2023
StartEst.
Jul 2023
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
May 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05864508
Responsible party
Sponsor
First posted
May 18, 2023
Start date
Jul 2023 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
May 18, 2023

Study contacts

Julie ANDANSON, MD
Contact
andanson.j@chu-toulouse.fr
05 61 77 80 75 ext. +33
Alexis REVET, MD, PhD
Contact
revet.a@chu-toulouse.fr
Julie ANDANSON, MD
principal investigator · Toulouse University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oxytocin

Start the discussion